Johnson & Johnson Innovative Medicine

Pharmaceutical Companies of Johnson and Johnson

Janssen Submits MA Application to the European MedicinesAgency Seeking Approval of Erdafitinib for the Treatment of Patients with LocallyAdvanced or Metastatic Urothelial Cancer with Susceptible FGFR Alterations

Pending approval, erdafitinib, an investigational, once-daily oral pan-fibroblast growth factorreceptor (FGFR) tyrosine kinase inhibitor, will become the first therapy targeting FGFRalterations in patients with metastatic urothelial carcinoma, one of Europe’s most commoncancers. The submission is based on results from the phase 3 THOR study, which were featured in aLate-Breaking Presentation Session at the 2023 ASCO...
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

0800 731 5550